Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
Stopped The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
- DRUG: LY3556050
- DRUG: Placebo
Sponsor
Eli Lilly and Company